A Phase 2 Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy After Surgery in Patients With High-Risk Endometrial Cancer: A Korean Gynecologic Oncologic Group Study


      A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer.

      Methods and Materials

      Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m2 was administered once weekly for 5 weeks during radiation therapy.


      Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively.


      Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal A.
        • Bray F.
        • Center M.M.
        • et al.
        Global cancer statistics.
        CA Cancer J Clin. 2011; 61: 69-90
        • Kuwabara Y.
        • Susumu N.
        • Banno K.
        • et al.
        Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
        Jpn J Clin Oncol. 2005; 35: 23-27
        • Aalders J.
        • Abeler V.
        • Kolstad P.
        • et al.
        Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients.
        Obstet Gynecol. 1980; 56: 419-427
        • Thigpen J.T.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study.
        J Clin Oncol. 2004; 22: 3902-3908
        • Mundt A.J.
        • McBride R.
        • Rotmensch J.
        • et al.
        Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy.
        Int J Radiat Oncol Biol Phys. 2001; 50: 1145-1153
        • Alvarez Secord A.
        • Havrilesky L.J.
        • Bae-Jump V.
        • et al.
        The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
        Gynecol Oncol. 2007; 107: 285-291
        • Choy H.
        • Rodriguez F.F.
        • Koester S.
        • et al.
        Investigation of taxol as a potential radiation sensitizer.
        Cancer. 1993; 71: 3774-3778
        • Frigerio L.
        • Mangili G.
        • Aletti G.
        • et al.
        Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: First feasibility study.
        Gynecol Oncol. 2001; 81: 53-57
        • Vogt H.G.
        • Martin T.
        • Kolotas C.
        • et al.
        Simultaneous paclitaxel and radiotherapy: Initial clinical experience in lung cancer and other malignancies.
        Semin Oncol. 1997; 24 (S112-105): S12-S101
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • et al.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study.
        J Clin Oncol. 2006; 24: 36-44
        • Sutton G.
        • Axelrod J.H.
        • Bundy B.N.
        • et al.
        Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A Gynecologic Oncology Group study.
        Gynecol Oncol. 2005; 97: 755-763
        • Hoskins P.J.
        • Swenerton K.D.
        • Pike J.A.
        • et al.
        Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study.
        J Clin Oncol. 2001; 19: 4048-4053
        • Aoki Y.
        • Kase H.
        • Watanabe M.
        • et al.
        Stage III endometrial cancer: Analysis of prognostic factors and failure patterns after adjuvant chemotherapy.
        Gynecol Oncol. 2001; 83: 1-5
        • Greven K.
        • Winter K.
        • Underhill K.
        • et al.
        Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.
        Gynecol Oncol. 2006; 103: 155-159
        • Lissoni A.
        • Zanetta G.
        • Losa G.
        • et al.
        Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer.
        Ann Oncol. 1996; 7: 861-863
        • Woo H.L.
        • Swenerton K.D.
        • Hoskins P.J.
        Taxol is active in platinum-resistant endometrial adenocarcinoma.
        Am J Clin Oncol. 1996; 19: 290-291
        • Aapro M.S.
        • van Wijk F.H.
        • Bolis G.
        • et al.
        Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
        Ann Oncol. 2003; 14: 441-448
        • Choy H.
        • Akerley W.
        • Safran H.
        • et al.
        Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
        J Clin Oncol. 1994; 12: 2682-2686
        • Wolf M.
        • Faoro C.
        • Goerg C.
        • et al.
        Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer.
        Semin Oncol. 1996; 23: 108-112
        • Jhingran A.
        • Ramondetta L.M.
        • Bodurka D.C.
        • et al.
        A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.
        Gynecol Oncol. 2013; 129: 304-309
        • Fowler J.M.
        • Brady W.E.
        • Grigsby P.W.
        • et al.
        Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.
        Gynecol Oncol. 2009; 112: 553-557
        • De Marzi P.
        • Frigerio L.
        • Cipriani S.
        • et al.
        Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: A clinical experience.
        Gynecol Oncol. 2010; 116: 408-412


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.